Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension.

Autor: Ait‐Oudhia, Sihem, Jaworowicz, David, Hu, Ziheng, Bihorel, Sébastien, Hu, Shuai, Balasubrahmanyam, Budda, Mistry, Bipin, de Oliveira Pena, Janethe, Wenning, Larissa, Gheyas, Ferdous

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology; Aug2024, Vol. 13 Issue 8, p1380-1393, 14p

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis

Autor: Distler, Oliver, Pope, Janet, Denton, Chris, Allanore, Yannick, Matucci-Cerinic, Marco, de Oliveira Pena, Janethe, Khanna, Dinesh

Publikováno v: In Respiratory Medicine January 2017 122 Supplement 1:S14-S17

Population Health Model Predicting the Long-Term Impact of Sotatercept on Morbidity and Mortality in Patients with Pulmonary Arterial Hypertension (PAH).

Autor: McLaughlin, Vallerie, Alsumali, Adnan, Liu, Rongzhe, Klok, Rogier, Martinez, Eliana C., Nourhussein, Iman, Bernotas, David, Chevure, Jestinah, Pausch, Christine, De Oliveira Pena, Janethe, Lautsch, Dominik, Hoeper, Marius M.

Publikováno v: Advances in Therapy; Jan2024, Vol. 41 Issue 1, p130-151, 22p

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Autor: Gibbs, J. Simon R., Gomberg-Maitland, Mardi, Souza, Rogerio, Manimaran, Solaiappan, Barnes, Jennifer, Linde, Peter, de Oliveira Pena, Janethe, Badesch, David, PULSAR Trial Investigators: PULSAR Trial Investigators: Badesch, David, Humbert, Marc, McLaughlin, Vallerie, Gibbs, Simon, Gomberg-, Mardi, Maitland, Maitland, Hoeper, Marius, Preston, Ioana, de Souza, Rogerio, Waxman, Aaron, Adir, Yochai, Andrade Lima, Marina, Argula, Rahul, Baratz, David, Barberá, Joan, Bar-Shai, Amir, Berasagui, Cristina, Bertoletti, Laurent, Blanco, Daniela, Bourdin, Arnaud, Campos, Frederico, Church, Colin, Cifrian Martinez Jose, Manuel, Gerry Coghlan, John, Demarco, Teresa, Eisenmann, Stephan, Engel, Peter, Escribano Subias, Pilar, Feenstra, John, Feldman, Jeremy, Halank, Michael, Howard, Luke, Keogh, Anne, Kramer, Mordechai, LANGE, Tobias, Meyer, Gisela, Montani, David, Olsson, Karen, Ota Arakaki, Jaquelina, Pison, Christophe, Reeves, Glenn, Rischard, Franz, Safdar, Zeenat, Saggar, Rajeev, Segel, Michael, Segovia Cubero, Javier, Spikes, Leslie, Shitrit, David, Wheatley, John, t Wirtz, Huber, Brundage Bruce, Ford, Neufeld, Ellis, McGoon, Michael

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2021, 384 (13), pp.1204-1215. ⟨10.1056/NEJMoa2024277⟩

International audience; BACKGROUND: Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is associated with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e233723e2e226c41b06b76c0b2a81e7
https://hal.archives-ouvertes.fr/hal-03270003/document

SPECTRA Phase 2b Study: Impact of Sotatercept on Exercise Tolerance and Right Ventricular Function in Pulmonary Arterial Hypertension

Autor: Waxman, Aaron B., Systrom, David M., Manimaran, Solaiappan, de Oliveira Pena, Janethe, Lu, Jonathan, Rischard, Franz P.

Publikováno v: Circulation: Heart Failure; May 2024, Vol. 17 Issue: 5 pe011227-e011227, 1p